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Minocycline differentially modulates human spatial
memory systems
Sam C. Berens 1, Chris M. Bird1 and Neil A. Harrison 2,3
Microglia play a critical role in many processes fundamental to learning and memory in health and are implicated in Alzheimer’s
pathogenesis. Minocycline, a centrally-penetrant tetracycline antibiotic, inhibits microglial activation and enhances long-term
potentiation, synaptic plasticity, neurogenesis and hippocampal-dependent spatial memory in rodents, leading to clinical trials in
human neurodegenerative diseases. However, the effects of minocycline on human memory have not previously been investigated.
Utilising a double-blind, randomised crossover study design, we recruited 20 healthy male participants (mean 24.6 ± 5.0 years) who
were each tested in two experimental sessions: once after 3 days of Minocycline 150 mg (twice daily), and once 3 days of placebo
(identical administration). During each session, all completed an fMRI task designed to tap boundary- and landmark-based
navigation (thought to rely on hippocampal and striatal learning mechanisms respectively). Given the rodent literature, we
hypothesised that minocycline would selectively modulate hippocampal learning. In line with this, minocycline biased use of
boundary- compared to landmark-based information (t980= 3.140, p= 0.002). However, though this marginally improved
performance for boundary-based objects (t980= 1.972, p= 0.049), it was outweighed by impaired landmark-based navigation
(t980= 6.374, p < 0.001) resulting in an overall performance decrease (t980= 3.295, p= 0.001). Furthermore, against expectations,
minocycline significantly reduced activity during memory encoding in the right caudate (t977= 2.992, p= 0.003) and five other
cortical regions, with no significant effect in the hippocampus. In summary, minocycline impaired human spatial memory
performance, likely through disruption of striatal processing resulting in greater biasing towards reliance on boundary-based
navigation.
Neuropsychopharmacology (2020) 0:1–8; https://doi.org/10.1038/s41386-020-00811-8
INTRODUCTION
Progress in psychoneuroimmunology over the last 2–3 decades
has revealed that medial temporal lobe (MTL) memory systems
are heavily dependent on immunoregulatory pathways. Further-
more, interactions between peripheral and central (brain) immune
systems can impair MTL-dependent memory [1, 2], and are
implicated in the aetiology of many neurodegenerative disorders
including Alzheimer’s disease [3]. Microglia (resident brain innate
immune cells) play a key role in many processes fundamental to
memory function in health including long-term potentiation (LTP)
and neural plasticity, homoeostatic synaptic scaling, and neuro-
genesis [4, 5]. They are also strongly implicated in the aetiology
and progression of Alzheimer’s and other neurodegenerative
diseases [6] making them an attractive target for novel disease-
modifying immunotherapies.
Medial temporal lobe structures appear to be particularly
sensitive to the effects of inflammation. This is perhaps due to
their relatively high density of microglia, the cytokine interleukin-
1β (IL-1β), its receptor, and its naturally occurring antagonist
(IL-1ra) [7, 8]. Within the hippocampus, IL-1β gene expression
increases during, or shortly after learning [9] and appears critical
to the maintenance of long-term potentiation (LTP) [10]. Similarly,
microglial release of tumour necrosis factor (TNF-α) is implicated
in the regulation of hippocampal synaptic scaling [11]. Microglia
also play a central role in synaptic pruning and plasticity [12] and
are the likely source of TNF, which is both necessary and sufficient
for homoeostatic synaptic scaling [13]. Under quiescent condi-
tions, microglia support adult neurogenesis within the hippocam-
pus [14], though their role in human striatal neurogenesis [15] is
yet to be investigated. Within the hippocampus, microglia have
also been implicated in the beneficial effects of environmental
enrichment on neurogenesis [16]. In health, these actions assist in
the remodelling of neural circuits to promote learning and
memory [4].
In contrast to their role in healthy cognition, activation of
microglia from resting to pro-inflammatory states is linked to
impaired memory, suppression of hippocampal neurogenesis
[17, 18] and the pathophysiology of Alzheimer’s and other
neurodegenerative diseases [6]. They have also been implicated in
obesity-associated cognitive impairments [19]. Minocycline, a
centrally penetrant tetracycline antibiotic, has been shown to inhibit
microglial activation and reverse inflammation-associated suppres-
sion of neurogenesis via mechanisms that appear distinct from its
antimicrobial action [17]. In rodent Alzheimer models, minocycline
attenuates neuronal cell death and improves cognitive impairment,
as measured by hippocampus-dependent memory tasks [20]. More-
over, in healthy aged animals, it improves hippocampus-dependent
spatial memory (water maze acquisition) [21]. Nevertheless, in both
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of these studies, minocycline had no beneficial effects on cognition
in the healthy adult control animals, suggesting benefits on memory
performance might be apparent only in animals with a compro-
mised hippocampal system. In terms of its actions at the cellular
level, minocycline reduces total microglia cell counts [21], enhances
hippocampal (CA1) LTP and augments dendritic spine density [22] in
healthy aged animals. In addition, in healthy (non-aged) animals it is
associated with increased hippocampal neurogenesis [21].
Together, these findings support the benefits of minocycline in
disease and have motivated a number of human clinical trials.
However, it remains unclear whether minocycline confers beneficial
or deleterious effects in healthy animals. Furthermore, studies of
the therapeutic effects of minocycline across a range of human
disorders including HIV-associated cognitive impairment [23],
Schizophrenia [24] and mild Alzheimer’s disease [25] have been
disappointing. In Motor Neuron Disease, minocycline has even been
associated with accelerated functional decline [26].
Despite its use in numerous preclinical rodent studies and
human clinical trials, the effects of minocycline on healthy human
memory have yet to be investigated. To address this, we recruited
20 healthy male participants and tested them during fMRI on a
spatial memory task designed to tap boundary- and landmark-
based navigation (thought to depend on hippocampal and striatal
learning mechanisms respectively). Each participant was tested in
two experimental sessions: once after 3 days of Minocycline
150mg (twice daily), and once 3 days of twice daily placebo
utilising a double-blind, randomised crossover study design. Based
on the rodent literature, we predicted minocycline would
selectively modulate hippocampal versus striatal-based learning
mechanisms.
MATERIALS AND METHODS
Participants
Twenty healthy, male right-handed non-smokers were recruited
from the University of Sussex (UK) via online advertisement. All
reported no history of neurological, psychiatric or immunological
disorder, were medication-free and had either normal or corrected-
to-normal vision. Females were excluded owing to the teratogenic
potential of minocycline. Two participants were subsequently
excluded due to technical difficulties with the virtual navigation
task and data from 18 participants are reported (mean age: 24.55
years, SD: 5.03). The study was approved by the Brighton and Sussex
Medical School Research Governance and Ethics Committee. All
participants provided written informed consent and were compen-
sated for their time.
Study design
The study utilised a cross-over repeated measures design in which
all participants were tested twice; once following minocycline, and
once placebo. Minocycline (150 mg) or visually identical placebo
was administered twice daily for 3 days prior to each study
session. The order of minocycline vs placebo administration was
counterbalanced across participants and the two study sessions
were separated by at least 14 days.
Spatial memory task
During fMRI, participants performed a modified version of a task
designed to simultaneously tap two interacting learning systems
that support spatial navigation [26]. This task has previously been
used to show that these systems, which encode location with
respect to environmental boundaries or an environment land-
mark, are differentially reliant on the hippocampus and dorsal
striatum respectively [27]. The virtual environment was con-
structed in Unreal Engine 2 (Epic Games) and consisted of a
circular grassy arena surrounded by a steep bank (boundary) and
a non-centrally located traffic cone (landmark). Background
mountains, clouds, and the sun projected at infinity were used to
provide orientation cues without allowing location to be inferred
by proximity or parallax. The boundary and landmark were both
rotationally symmetric to avoid providing orientation informa-
tion (Fig. 1a).
Participants’ goal was to learn the spatial location of four
everyday objects placed in the arena. At the start of the task,
participants entered the virtual arena with one object already in
place. After identifying its location, they collected the object by
walking over it. This was then repeated for each of the four
objects. Participants then used trial-and-error learning to progres-
sively improve how accurately they could relocate each object.
This phase of the task consisted of three consecutive blocks, with
each block containing 16 separate trials (four per object). Each trial
started with an image of one of the objects presented for 2 s
against a grey background (CUE). After a further 2–6 s delay
participants were returned to the virtual environment at a random
location without the object present (initial heading directions and
start positions were randomly sampled from a uniform distribu-
tion, constrained to an area of two virtual metres in the centre of
the arena). They were then required to move to where they
believed the cued object was located and press a button
(REPLACE). Immediately afterwards the true location of the object
was revealed (FEEDBACK), and participants re-collected the object
by walking over it. This final FEEDBACK phase allowed participants
to progressive refine their memory regarding the true location of
that object (Fig. 1b). Different objects, backdrops, and trained
locations were used for each of the two separate testing sessions.
Furthermore, object assignments to each navigational condition,
the order of landmark/boundary shifts (see below), the distal
backdrops, and the trained locations themselves were all counter-
balanced across sessions.
To experimentally manipulate the use of the two (boundary vs
landmark) navigational strategies two objects were assigned to a
‘boundary-related’ condition (B-RELATED), and two a ‘landmark-
related’ (L-RELATED) condition. The relative position of the
landmark and the boundary shifted twice during the task (at
the start of blocks 2 and 3; not explicit in task instructions to
mitigate potential demand characteristics). Note: these shifts
should be properly understood as relative changes in landmark/
boundary position since these cues were the only objects that
provided proximity information in the environment. Following
each shift, B-RELATED objects maintained a fixed position with
respect to the boundary and L-RELATED objects a fixed position
relative to the landmark (Fig. 1c). Consequently, during the
FEEDBACK phase of blocks 2 and 3, the boundary and the
landmark became differentially informative with respect to
learning the locations of B- and L-RELATED objects. Of note, the
landmark/boundary shifts were not restricted to simple rotations.
This made it more likely that each object location was learned
relative to its associated navigation cue since proximity and
angular distance were both relevant. This task was identical to that
used by Doeller et al. [27] with the exception that the original
study involved four blocks rather than the three used here.
Behavioural data analysis
Location estimates during the REPLACE phase were used to calculate
drop-errors (in virtual metres) reflecting the absolute distance
between estimated and true object locations during each trial.
Drop-errors for each participant and trial were analysed using a
generalised linear mixed-effects model (GLMM) with four fixed-effect
predictors and their interactions: (1) drug (minocycline vs placebo),
(2) navigational condition (landmark- vs boundary-related objects),
(3) experimental block (block 2 vs 3), and (4) trial number (i.e. trials 1
to 4). Of note: As the distinction between landmark- and boundary-
related objects was not made apparent until the start of block 2, data
acquired prior to this point were not included in the analysis.
Random-effect predictors were used to account for statistical
dependencies between observations from the same participant
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and object. Drop errors were all non-negative and distributed with a
large positive skew that closely approximated an Inverse-Gaussian
distribution. Thus, the GLMM used an Inverse-Gaussian to para-
meterise the distribution of drop-errors with a log link-function to
constrain predicted scores between 0 and positive infinity.
Following Doeller et al. [27], we also generated a metric
(LB-influence) to quantify the relative influence of each naviga-
tional cue (landmark vs boundary) on REPLACE performance. We
first calculated the distance between each replaced location, and
the location of that object as predicted by either the boundary
(dB) or the landmark (dL). LB-influence was then calculated as the
ratio of dL to the sum of dB and dL i.e. dL ÷ (dB+ dL). This metric
varies between 0 and 1 with low values indicating greater reliance
on the landmark, and higher values (closer to 1) greater reliance
on the boundary. As an example, for an L-related object, dL is
simply the drop-error and dB the distance between the replaced
location and the boundary-related location that would have been
correct prior to the most recent landmark shift. We again used a
GLMM to estimate how LB-influence was modulated as a function
of drug, navigational condition, block, and trial. This model had
the same fixed- and random-effects structure as that used in the
drop-error analysis. However, given that LB-influence scores are
bounded between 0 and 1, the model used a logit link function to
constrain predicted scores to this interval.
Based on the results of prior studies, we predicted that drop-
errors would gradually decrease for all objects in each block.
Similarly, we predicted that LB-influence scores would gradually
diverge from ~0.5 (equal landmark- and boundary-influence)
towards 0 or 1 for L-, and B-related objects, respectively.
We therefore performed a linear contrast across the parameter
estimates from trails 1 to 4 to test the main effects and
interactions related to trial-by-trial differences.
Fig. 1 Virtual navigation task. a Examples of the two virtual environments. b Schematic illustration of the task procedure. c Examples of how
the landmark, boundary and their associated objects moved relative to each other over the course of three blocks in order to train landmark
vs boundary-based navigation. Within each block, there were four learning trials per object.
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Effect of participant BMI
Obesity has been associated with deleterious effects on the CNS
including accelerated age-related cognitive decline and medial
temporal lobe (particularly hippocampal) atrophy in humans [19].
This has been linked to increased microglial activation and the
release of IL-1β in rodents [19]. Given this, we performed a
secondary analysis to explore possible interactions between body
mass index (BMI) and effects of minocycline on behavioural
performance using additional GLMMs of drop error and LB-
influence statistics that included participant BMI as a continuous
covariate (range: 17.57–31.40, mean centred). BMI was permitted
to interact with the effects of drug, navigational condition, and
their interaction to enable us to test for differential effects of
minocycline in participants with different BMIs (for landmark vs
boundary objects separately). However, to limit the number of
fixed effects coefficients, we did not permit BMI to interact with
experimental block or trial number. These interactions were found
not to significantly interact with minocycline (see results), and the
additional model complexity was not warranted based on model
fit statistics (Bayesian Information Criterion) [28].
MRI analyses
Details of the imaging protocol and pre-processing steps are
provided in the Supplementary Methods. First-level fMRI models
included individual boxcar regressors for the CUE, REPLACE, and
FEEDBACK phases of each trial, an intercept term, and 12 motion
parameters (realignment parameters and their first derivatives).
First-level beta coefficient images from each participant and
session were then used in two second-level linear mixed-effects
models (LMM) to model BOLD activations during memory retrieval
(REPLACE), and memory encoding (FEEDBACK). As previous work
has demonstrated that the hippocampus and striatum differen-
tially contribute to boundary- and landmark-based navigation
[27, 29] we focused these analyses on four regions of interest
(ROIs): the left and right hippocampus, and the left and right
caudate nuclei (defined using the AAL atlas; shown in Supple-
mentary Fig. S1) [30]. Specifically, average BOLD activity during
each REPLACE/FEEDBACK trial was extracted for each ROI.
To supplement our main analyses, we also examined BOLD
effects outside our four ROIs using LMMs of the REPLACE and
FEEDBACK data in 400 non-overlapping brain parcels (derived
from a whole-brain parcellation by Schaefer et al. [31]).
The LMMs for memory retrieval (REPLACE) included four
predictors of interest: (1) drug (minocycline vs placebo), (2)
navigation condition (landmark- vs boundary-related objects), (3)
LB-influence, (4) participant BMI, and all possible interactions
between them (note: the inclusion of each model term was
informed by the results of our behavioural analysis, as below).
As LB-influence is believed to represent the relative contribution
of landmark and boundary cues to navigation performance, we
predicted this would correlate with BOLD activity during the
replace phase. The LMM for memory encoding (FEEDBACK) also
included four predictors: (1) drug (minocycline vs placebo), (2)
navigation condition (landmark- vs boundary-related objects), (3)
drop-error, and (4) participant BMI, and all possible interactions
between them. Here, we assumed that drop-error statistics directly
corresponded to prediction error during feedback, and in turn,
reflect the degree of memory encoding [32].
As for the behavioural analyses, data acquired prior to trial 2 of
block 2 were not included in either LMM of the fMRI data since the
distinction between landmark- and boundary-related objects was
not made apparent until this point. LB-influence and drop-error
were logit- and log-transformed respectively before being
z-scored to ensure that the sampling distribution of model
parameters was approximately normal. In addition, by removing
all bounds on the predictor values, these transforms allowed any
changes in LB-influence and drop-error to be associated with
meaningful differences in BOLD activity. Trial number was not
included as a predictor in either LMM as behavioural results
revealed that this was largely co-linear with both LB-influence and
drop-error (see ‘Results’). Both LMMs also included random
intercepts and slopes for each fixed effect factor. These accounted
for statistical dependencies related to observations from the same
participants, task blocks and objects.
RESULTS
Behavioural task
Drop-error data (FEEDBACK) as a function of navigational
condition, trial number and drug are displayed in Fig. 2 (top
row). As anticipated, the GLMM identified a significant main effect
of trial indicating that drop errors for both L- and B-related objects
decreased as training progressed: t980= 11.035, p < 0.001. The
model also highlighted a significant trial by navigation condition
interaction, t980= 2.922, p= 0.004, with the reduction in drop
errors occurring more rapidly for boundary- relative to landmark-
following objects. In line with our prior prediction, we also
observed a significant drug by navigation condition interaction,
t980= 5.264, p < 0.001. Although analysis of this interaction
showed our predicted reduction in drop errors for boundary-
related objects on minocycline, t980= 1.972, p= 0.049, it also
showed that minocycline increased drop errors for L-related
objects, t980= 6.374, p < 0.001. Furthermore, we also observed a
significant main effect of drug with drop errors being significantly
greater (i.e. worse performance overall) when on minocycline
versus placebo, t980= 3.295, p= 0.001.
We next examined the effects of minocycline on LB-influence
(REPLACE) scores (Fig. 2, bottom row). Firstly, this identified a main
effect of navigational condition confirming that LB-influence
scores were significantly higher for B- compared to L-related
objects, t980= 23.940, p < 0.001. We also observed the expected
navigation condition by trial interaction with LB-influence
increasing for B- and decreasing for L-related objects as training
progressed: t980= 9.900, p < 0.001. However, the model further
revealed a main effect of drug indicating that LB-influence scores
were, in general, higher (more dependent on boundary) when on
minocycline, t980= 3.140, p= 0.002.
Fig. 2 Behavioural performance on the virtual navigation task.
Drop error statistics (top row) and LB-influence scores (lower row)
broken down by drug, navigation condition and trial number. Error
bars represent ±95% confidence intervals. VM= virtual metres.
Significant difference in LB-influence scores on trial 1 are observed
as this analysis only included trials after object locations were
differentially trained.
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This suggests that minocycline enhances the use of boundary-
compared to landmark-based navigational systems. Our drop-
error findings suggest that this may marginally improve
navigational performance for boundary-based objects, but this
is outweighed by impaired landmark-based navigation resulting
in an overall decrease in performance. In support of this, we
observed no significant drug by navigation condition interaction
on LB-influence: t980= 0.070, p= .944 suggesting that minocy-
cline boosts use of boundary- compared to landmark-based
navigational systems, even in conditions where this adversely
affects performance.
Effects of BMI on behaviour
Inclusion of BMI in the models identified two further significant
effects of interest in the analysis of drop errors: A significant BMI
by drug interaction (t976= 4.276, p < 0.001) and a three-way
interaction between BMI, drug, and navigation condition (t976=
3.442, p < 0.001) that superseded this. This indicated that the
degree to which landmark related navigation was adversely
affected by minocycline was dependent on participant BMI, i.e.
minocycline had a more detrimental effect when BMI was lower,
and this effect was specific to the landmark-related condition
(Fig. 3). No significant main effects of BMI, or a BMI by navigation
condition interaction (t976’s < 1.096, p’s > 0.273) were observed,
though the inclusion of BMI led to the beneficial effect of
minocycline on boundary-related drop errors falling below the
threshold of statistical significance, t976= 1.689, p= 0.092.
BOLD effects related to spatial navigation
We first examined whether landmark and boundary-based
navigation were associated with differential levels of activity in
our four ROIs. Here, we only looked for effects that were evident in
the placebo condition so that the results were not influenced by
any potential effects of minocycline. During the REPLACE phase
(memory retrieval) we observed no significant main effects or
interactions between navigation condition and LB-influence in any
ROI (largest effect: t982= 1.260, p= 0.208). Similarly, during the
FEEDBACK phase (memory encoding) we observed no significant
main effects or interactions between navigation condition and
drop error (largest effect: t973= 1.403, p= 0.161). As such, we
failed to find any evidence of functional specialisation in our a
priori ROIs.
In contrast, our whole-brain analyses did identify spatial
memory effects of interest. Specifically, a number of regions
exhibited a negative correlation between drop error and BOLD
activity during the FEEDBACK phase of both landmark- and
boundary-related trials (see Supplementary Fig. S2). This implies
that more accurate responses were associated with higher
levels of BOLD activity in both navigation conditions in these
regions. Regions showing this effect included a large cluster
in the lingual gyrus extending into the fusiform gyrus and
posterior hippocampus (bilaterally). On the left side, this cluster
also included a region of the retrosplenial cortex. Furthermore,
bilateral effects were observed in the inferior parietal lobe,
superior temporal gyrus, inferior frontal gyrus, and anterior
cingulate cortex. No other effects of interest were detected in
the placebo session during either the REPLACE or FEEDBACK
phases.
Effects of minocycline
The ROI analyses revealed that minocycline was associated with a
significant reduction in right caudate activity during memory
encoding (FEEDBACK) regardless of navigational condition (main
effect of minocycline: t977= 2.992, p= 0.003; Fig. 4). A similar
though non-significant effect was also observed in the left
caudate (t973= 1.924, p= 0.053). The ROI analyses found no other
main effects or interactions involving minocycline during either
the REPLACE or FEEDBACK phases.
To test whether minocycline exerted a statistically larger
effect in the caudate than the hippocampus ROIs, we compared
the main effect of minocycline during FEEDBACK across regions
within the same hemisphere using an unequal variances
t-test (residual degrees of freedom were approximated with
the Welch-Satterthwaite equation [33]). These comparisons
confirmed a larger effect in the right, but not the left caudate;
t1492= 2.288, p= 0.022 and t1672= 1.179, p= 0.239, respec-
tively. Taken together, these results demonstrate that right
caudate activity during both landmark- and boundary-based
navigation, was attenuated under minocycline.
The whole-brain analysis also revealed significant main effects
of minocycline during the FEEDBACK phase in five other cortical
Fig. 3 Relationship between body mass index (BMI) and drop
errors (accuracy) in the virtual-navigation task plotted by
experimental condition. a drop error scores from the landmark-
related condition, b drop error scores from the boundary-related
condition. Grey and coloured shadings relate to the placebo and
minocycline sessions, respectively. Error bars indicate 95% con-
fidence intervals.
Fig. 4 Mean estimates of BOLD activity during FEEDBACK
(memory encoding) in all a priori ROIs plotted by experimental
condition: navigation type (landmark vs boundary) and drug
(placebo vs minocycline). Each panel corresponds to a different
ROI—a left hippocampus; b right hippocampus; c left caudate;
d right caudate. Grey and coloured shadings relate to the placebo
and minocycline sessions, respectively. Error bars indicate 95%
confidence intervals.
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regions (see Supplementary Fig. S3). These were located in the
visual cortex bilaterally (V1–V3), the right inferior parietal lobe, and
right middle frontal gyrus. As above, each of these effects
indicated that minocycline was associated with a significant
reduction in BOLD activity during memory encoding regardless of
navigational condition. No other main effects or interactions
involving minocycline, including any interactions with BMI, were
detected across analyses.
DISCUSSION
Here we show that minocycline differentially modulated memory
performance: moderately reducing errors during boundary-
based navigation yet increasing landmark-based replacement
errors. Related to this, minocycline appeared to enhance
participants’ reliance on boundary- compared to landmark-
based learning systems during navigation. These findings are
broadly in line with our predictions that minocycline would
modulate hippocampal-mediated memory performance which is
thought to underpin boundary-based navigation. Importantly,
however, the boost in performance for boundary-based naviga-
tion was only modest, while the impairment of landmark-based
navigation was substantial, and together these effects resulted in
an overall impairment in spatial memory performance. Further-
more, the moderate reduction in boundary-related errors was
transient, being evident only at the early stages of learning when
boundary-related information is known to take precedence
[34, 35]. Minocycline-induced impairments in landmark-based
navigation were also more pronounced in participants with low
or normal BMI (i.e. <25).
Our imaging data are consistent with the interpretation that
minocycline exerted more of a negative effect on landmark-based
navigation than a positive effect on boundary-based navigation;
minocycline was associated with a significant reduction in BOLD
activity in the right striatum. This was evident when participants
received error-related feedback. Although we did not find the
predicted relationship between striatal activity and behavioural
performance, previous research has heavily implicated the
striatum in guiding learning by processing prediction error signals
[36]. Furthermore, this mechanism is thought to be particularly
relevant to landmark-related navigation [37]. Aside from this
reduction in striatal activity, we also identified a number of similar
effects in five other cortical regions including the visual cortex
(V1–V3), inferior parietal lobe, and middle frontal gyrus where
minocycline was associated with a significant reduction in BOLD
activity during memory encoding regardless of navigational
condition.
Importantly, the effects of minocycline on both behavioural
performance and BOLD activity were evident regardless of
whether landmark- or boundary-related information was being
processed. Thus, although landmark-based navigation may be
particularly dependent on striatal function, our results suggest
that this region also influences boundary-based navigation. In line
with this, we found no evidence that landmark- or boundary-
based navigation differentially activated either the hippocampus
or the striatum, thought the posterior hippocampus did exhibit
BOLD effects that tracked trial-by-trial retrieval success. This
contrasts with findings from a previous fMRI study which reported
that boundary-based navigation preferentially activates the
hippocampus, and landmark-based navigation the striatum [27].
The reasons for this discrepancy are not clear, however, it is
notable that a number of other studies have suggested that there
is no strict functional dichotomy between the hippocampal and
striatal nuclei during navigation [38–40].
Our results are consistent with those from the rodent literature
which have reported moderate benefits of minocycline on
hippocampally-mediated memory processes, though only in either
aged animals [21] or rodent models of Alzheimer’s [20]. In addition,
while we did not explicitly predict the negative effect of minocycline
on landmark-based navigation and striatal function, these results are
perhaps unsurprising given that microglia play multiple roles in
supporting healthy cognition by coordinating a wide array of
fundamental processes linked to learning and memory [4].
Furthermore, the antimicrobial effects of minocycline are likely to
disrupt the gut microbiota which indirectly influences memory
performance by modulating LTP and neurogenesis [41, 42].
Another notable finding was that the detrimental effects of
minocycline on behaviour were negatively related to BMI, with more
detrimental effects observed in low or normal weight (BMI < 25)
individuals. This may simply reflect a dose-dependent relationship
since the minocycline dose was not adjusted by participant mass.
However, it may also relate to the differential effects of inhibiting
microglial activation reported in rodents where both microglial and
microbiota functions are known to depend on metabolic status
[43, 44]. In particular, while microglia play important roles in
sustaining cognitive performance in health, heightened microglial
activity in obesity has been linked to associated impairments in
cognition [43, 44]. Given this, the inhibitory effects of minocycline on
microglial activation may actually aid cognition in obesity. In line
with this, though minocycline was associated with poorer memory
performance in our sample of healthy individuals, we note that the
one individual with a BMI in the obese range (>30) actually showed
a modest improvement in memory performance on minocycline. As
such, our results hint that minocycline may have beneficial effects
on some aspects of cognition for this group, though this will clearly
need to be explicitly addressed in future studies.
It is notable that studies investigating the role of neuroin-
flammatory processes, microglia and effects of minocycline in
rodent learning have focussed almost exclusively on the medial
temporal lobes, particularly the hippocampus [4]. Within the
rodent hippocampus, microglia are thought to affect cognition via
modulation of LTP and neurogenesis [11, 16, 45, 46]. Our findings
suggest that minocycline also likely affects neuronal function in
other brain regions including striatum, which in normal-weight
individuals is associated with negative effects on behaviour.
Whether this results from direct effects of minocycline on
neuronal populations within these regions or from modulation
in functionally connected systems cannot be determined here.
However, irrespective of the neural mechanisms, the current
findings suggest that minocycline is unlikely to confer any
therapeutic benefit in treating or preventing generalised cognitive
decline involving neuroinflammatory processes and adds to a
growing body of evidence that minocycline offers negligible
neuroprotective effects [25, 47, 48].
In summary, we show that minocycline significantly modulates
learning and memory processes in healthy human participants.
Overall, this had the effect of decreasing memory performance,
particularly when learning spatial locations relative to landmarks.
This effect was most pronounced in participants with a low or
normal BMI (i.e. <25). Together, these observations lend additional
support to theories implicating microglia in learning and memory
functions in humans. Future studies probing the effects of
minocycline on other cognitive processes will be required to
support our findings and, in particular, investigate the potential for
any beneficial effect of minocycline in obesity. Intracranial
electrode recordings would allow a direct examination of
minocycline’s effects of neuronal firing rates and synaptic
potentiation in different brain regions. Furthermore, Translocator
(TSPO) positron emission tomography [49–51] could direct
investigate whether the cognitive effects of minocycline directly
correspond to microglial activity.
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